Earth Science Tech Inc. (ETST) Builds Telehealth, Pharmacy Links in Evolving Digital Care
- Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care.
- DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation.
- ETST is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services.
Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside one digital pathway. That shift toward fully integrated platforms is changing expectations across healthcare, and Earth Science Tech’s (OTC: ETST) is building exposure to that trend through a portfolio that includes telemedicine platforms, compounding pharmacies and related healthcare services.
The logic behind integrated telehealth is straightforward. Patients increasingly want access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care. The American Medical Association’s telehealth integration toolkit notes that optimized virtual care workflows can improve patient care through more efficient delivery and better integration into routine practice.
The need for improved care and efficiency is reflected in the forecast for the telehealth space. DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation. “The telehealth market is largely propelled by the increasing prevalence of chronic diseases, which creates a growing demand for frequent medical consultations and ongoing patient monitoring, services that telehealth can effectively deliver,” the article noted. “Simultaneously, the broad adoption of smartphones, high-speed internet connectivity, and wearable health technologies supports smooth remote consultations and real-time health monitoring.
“Moreover, continuous product development by leading industry players is bringing advanced telehealth solutions to market, enhancing service quality and widening access to care,” the article continued. “Collectively, these factors are driving the expansion of telehealth, improving patient engagement and contributing to overall market growth.”
There is also a clinical and operational case for tighter integration. A 2025 study published in the “Journal of Health, Population and Nutrition” describes electronic prescribing as a key component of ehealth and says it can enhance healthcare efficiency, reduce errors, and support safer, more accurate medication management. A 2025 telepharmacy review similarly notes that remotely delivered pharmaceutical care can improve medication safety, strengthen continuity of care and reduce prescribing errors through structured pharmacist-led interventions. Together, those findings reinforce the core idea behind integrated telehealth platforms: Digital consultation becomes more valuable when it connects directly to medication management and care continuity rather than ending at the virtual visit.
At the same time, the rise of direct-to-consumer virtual care has raised questions about fragmentation. A 2026 scoping review of commercial virtual care found that such platforms have expanded rapidly over the past decade, but it also warned that virtual services not integrated into broader care systems can disrupt continuity of care and may increase utilization without improving outcomes. That tension helps explain why the “from consultation to prescription” model matters. The next competitive step is not just offering digital access; it is building a system where consultation, prescribing, pharmacy and follow-up are coordinated rather than isolated.
That broader industry trend provides useful context for Earth Science Tech. The company describes itself as a strategic holding company that acquires and actively manages operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and selected consumer markets. ETST’s healthcare-related holdings include telemedicine and pharmaceutical operations designed to support a more connected platform approach; in addition, its compounding operations through RxCompoundStore.com and Mister Meds directly align with the expanding digital healthcare segment.
Earth Science Tech recently reported that its operations include compounding pharmaceuticals, telemedicine, and real estate development through subsidiaries including RxCompoundStore.com, Mister Meds, Peaks Curative, DOConsultations, Las Villas Health Care, Avenvi, Earth Science Foundation and an 80% interest in MagneChef. That portfolio matters because it suggests the company is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services.
The telehealth angle becomes even more specific in descriptions of Peaks. Earth Science Tech described Peaks as a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds, noting that the platform operates in states where either pharmacy is licensed. The company also noted that it is building out its own healthcare provider network through MyOnlineConsultation.com while pursuing additional pharmacy licensure to expand the service footprint. That structure is a close fit with the “consultation to prescription” theme, because it links provider access, prescribing pathways and pharmacy capabilities under one corporate umbrella.
Earth Science Tech has also pointed to traction inside that model, noting that it is operating as a diversified portfolio across pharmaceutical, healthcare, telemedicine and consumer markets while emphasizing controlling interests, regulatory compliance, and disciplined scaling. Earlier this month, the company reported that Peaks had surpassed $2 million in revenue in less than a year and is pursuing additional state licenses. These reports suggest that ETST’s telemedicine-related assets are becoming commercially meaningful within the broader portfolio.
For investors, the company’s appeal in the telehealth space lies less in a pure-play software multiple and more in its attempt to build a vertically connected healthcare platform. ETST chairman and CEO Giorgio R. Saumat has described the business as a “a strategic holding company with core assets in healthcare, mostly compounding pharmaceuticals and online telehealth. We are creating a vertically integrated healthcare company. From the marketing side we have Peaks Curative, our online telehealth subsidiary, all the way through Mister Meds and RxCompoundStore.com that fulfill the patient.”
That framing is important because it aligns the company with a part of digital healthcare that could become increasingly valuable if the industry continues moving from isolated virtual appointments toward integrated models that can connect care access, medication prescribing and fulfillment.
As telehealth matures, the companies that stand out may be the ones that reduce friction after the appointment not just during it. Consultation alone is useful, but consultation linked to prescribing, pharmacy operations and follow-up can create a more complete care pathway. Earth Science Tech is working to build that kind of structure through its mix of telemedicine platforms, compounding pharmacy assets and healthcare subsidiaries, positioning itself within a digital care model that increasingly looks less like a video visit and more like an end-to-end service platform.
For more information, visit EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://nnw.fm/ETST
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Patients increasingly prefer access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care.
- DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation.
- ETST is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services.
Telehealth is evolving from a simple video visit into something far more comprehensive: a connected care model that can move a patient from consultation to prescription, fulfillment and follow-up inside one digital pathway. That shift toward fully integrated platforms is changing expectations across healthcare, and Earth Science Tech’s (OTC: ETST) is building exposure to that trend through a portfolio that includes telemedicine platforms, compounding pharmacies and related healthcare services.
The logic behind integrated telehealth is straightforward. Patients increasingly want access, speed and convenience, but healthcare systems also need better coordination, safer medication workflows and clearer continuity of care. The American Medical Association’s telehealth integration toolkit notes that optimized virtual care workflows can improve patient care through more efficient delivery and better integration into routine practice.
The need for improved care and efficiency is reflected in the forecast for the telehealth space. DelveInsights has projected that the global telehealth market will reach $2 trillion by 2034, driven by a digital healthcare transformation. “The telehealth market is largely propelled by the increasing prevalence of chronic diseases, which creates a growing demand for frequent medical consultations and ongoing patient monitoring, services that telehealth can effectively deliver,” the article noted. “Simultaneously, the broad adoption of smartphones, high-speed internet connectivity, and wearable health technologies supports smooth remote consultations and real-time health monitoring.
“Moreover, continuous product development by leading industry players is bringing advanced telehealth solutions to market, enhancing service quality and widening access to care,” the article continued. “Collectively, these factors are driving the expansion of telehealth, improving patient engagement and contributing to overall market growth.”
There is also a clinical and operational case for tighter integration. A 2025 study published in the “Journal of Health, Population and Nutrition” describes electronic prescribing as a key component of ehealth and says it can enhance healthcare efficiency, reduce errors, and support safer, more accurate medication management. A 2025 telepharmacy review similarly notes that remotely delivered pharmaceutical care can improve medication safety, strengthen continuity of care and reduce prescribing errors through structured pharmacist-led interventions. Together, those findings reinforce the core idea behind integrated telehealth platforms: Digital consultation becomes more valuable when it connects directly to medication management and care continuity rather than ending at the virtual visit.
At the same time, the rise of direct-to-consumer virtual care has raised questions about fragmentation. A 2026 scoping review of commercial virtual care found that such platforms have expanded rapidly over the past decade, but it also warned that virtual services not integrated into broader care systems can disrupt continuity of care and may increase utilization without improving outcomes. That tension helps explain why the “from consultation to prescription” model matters. The next competitive step is not just offering digital access; it is building a system where consultation, prescribing, pharmacy and follow-up are coordinated rather than isolated.
That broader industry trend provides useful context for Earth Science Tech. The company describes itself as a strategic holding company that acquires and actively manages operating businesses in pharmaceuticals, telemedicine, healthcare services, real estate, and selected consumer markets. ETST’s healthcare-related holdings include telemedicine and pharmaceutical operations designed to support a more connected platform approach; in addition, its compounding operations through RxCompoundStore.com and Mister Meds directly align with the expanding digital healthcare segment.
Earth Science Tech recently reported that its operations include compounding pharmaceuticals, telemedicine, and real estate development through subsidiaries including RxCompoundStore.com, Mister Meds, Peaks Curative, DOConsultations, Las Villas Health Care, Avenvi, Earth Science Foundation and an 80% interest in MagneChef. That portfolio matters because it suggests the company is not approaching telehealth as a standalone app or referral layer but as part of a broader operating structure that includes medication fulfillment capacity and patient-facing services.
The telehealth angle becomes even more specific in descriptions of Peaks. Earth Science Tech described Peaks as a telemedicine referral platform offering asynchronous consultations for Peaks-branded compounded medications prepared at RxCompound and Mister Meds, noting that the platform operates in states where either pharmacy is licensed. The company also noted that it is building out its own healthcare provider network through MyOnlineConsultation.com while pursuing additional pharmacy licensure to expand the service footprint. That structure is a close fit with the “consultation to prescription” theme, because it links provider access, prescribing pathways and pharmacy capabilities under one corporate umbrella.
Earth Science Tech has also pointed to traction inside that model, noting that it is operating as a diversified portfolio across pharmaceutical, healthcare, telemedicine and consumer markets while emphasizing controlling interests, regulatory compliance, and disciplined scaling. Earlier this month, the company reported that Peaks had surpassed $2 million in revenue in less than a year and is pursuing additional state licenses. These reports suggest that ETST’s telemedicine-related assets are becoming commercially meaningful within the broader portfolio.
For investors, the company’s appeal in the telehealth space lies less in a pure-play software multiple and more in its attempt to build a vertically connected healthcare platform. ETST chairman and CEO Giorgio R. Saumat has described the business as a “a strategic holding company with core assets in healthcare, mostly compounding pharmaceuticals and online telehealth. We are creating a vertically integrated healthcare company. From the marketing side we have Peaks Curative, our online telehealth subsidiary, all the way through Mister Meds and RxCompoundStore.com that fulfill the patient.”
That framing is important because it aligns the company with a part of digital healthcare that could become increasingly valuable if the industry continues moving from isolated virtual appointments toward integrated models that can connect care access, medication prescribing and fulfillment.
As telehealth matures, the companies that stand out may be the ones that reduce friction after the appointment not just during it. Consultation alone is useful, but consultation linked to prescribing, pharmacy operations and follow-up can create a more complete care pathway. Earth Science Tech is working to build that kind of structure through its mix of telemedicine platforms, compounding pharmacy assets and healthcare subsidiaries, positioning itself within a digital care model that increasingly looks less like a video visit and more like an end-to-end service platform.
For more information, visit EarthScienceTech.com.
NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at https://nnw.fm/ETST
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
